I wanted to share two great reads regarding CF advancements that have happened recently.

Genetic Diversity in Bacterial Strains May Explain Differences in Severity of CF Lung Infections

Chronic bacterial lung infections are the leading cause of death in CF. Genetic mutations in these patients affect ion transfer across mucus membranes. This leads to increased mucus production that provides an ideal habitat for bacterial infections.

Read More Here.

Tezacaftor (VX-661) for Cystic Fibrosis

Tezacaftor (VX-661) is a corrector developed by Vertex Pharmaceuticals. Tezacaftor aims to restore CFTR (cystic fibrosis transmembrane conductance regulator) gene function by moving the protein into the correct position on the cell surface. Tezacaftor is designed to treat people with cystic fibrosis (CF) who carry the F508del mutation.

Read More Here.